Aspira Women’s Health Inc. (NASDAQ:AWH) Sees Significant Increase in Short Interest

Aspira Women’s Health Inc. (NASDAQ:AWH) saw a significant growth in short interest in the month of June. As of June 30th, there was short interest totalling 269,300 shares, a growth of 13.0% from the June 15th total of 238,300 shares. Currently, 3.5% of the shares of the company are sold short. Based on an average trading volume of 92,300 shares, the days-to-cover ratio is presently 2.9 days.

Hedge Funds Weigh In On Aspira Women’s Health

An institutional investor recently raised its position in Aspira Women’s Health stock. Quantum Private Wealth LLC grew its position in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 76.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 50,156 shares of the company’s stock after buying an additional 21,788 shares during the quarter. Quantum Private Wealth LLC owned approximately 0.49% of Aspira Women’s Health worth $205,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 12.19% of the company’s stock.

Aspira Women’s Health Stock Performance

Shares of AWH stock traded down $0.06 during mid-day trading on Monday, reaching $1.55. The company’s stock had a trading volume of 115,717 shares, compared to its average volume of 64,504. The firm’s 50-day moving average is $2.01 and its two-hundred day moving average is $3.31. Aspira Women’s Health has a 1-year low of $0.86 and a 1-year high of $6.75. The company has a market cap of $19.30 million, a P/E ratio of -0.99 and a beta of 1.54.

Aspira Women’s Health (NASDAQ:AWH) last announced its quarterly earnings results on Tuesday, May 21st. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03). The business had revenue of $2.15 million for the quarter, compared to analysts’ expectations of $2.10 million. During the same period last year, the company posted ($10.94) EPS. Sell-side analysts anticipate that Aspira Women’s Health will post -1.3 EPS for the current year.

Analysts Set New Price Targets

AWH has been the topic of several research analyst reports. StockNews.com started coverage on shares of Aspira Women’s Health in a research report on Tuesday, July 2nd. They issued a “sell” rating on the stock. Cantor Fitzgerald restated a “neutral” rating and set a $3.30 price target on shares of Aspira Women’s Health in a research note on Wednesday, April 10th.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.